Northwest Biotherapeutics

Showcase Sponsor

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines.  The Company's DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and various potential  Phase II trials are anticipated, including in combination with checkpoint inhibitor drugs.  The Company's DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers,  and various potential Phase II trials are anticipated.


website

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071